Interviews

Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.

Anees B. Chagpar, MD, MPH, MBA, Yale Comprehensive Cancer Center, discusses contralateral prophylactic mastectomy for patients with breast cancer.

Alok Khorana, MD, discusses the long-term impacts of tinzaparin versus warfarin, as well as clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients, in the CATCH study.

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

James Kearns, MD, discusses genetic correction of prostate-specific antigen (PSA) and how it can reduce the number of patients diagnosed with potentially insignificant prostate cancer

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses the impact of immunotherapy in prostate cancer.

Melvin J. Silverstein, MD, FACS, Hoag Memorial Hospital Presbyterian, discusses the benefits of oncoplastic surgery for patients with breast cancer.

Matthew H. Taylor, MD, Oregon Health and Science University, discusses the toxicities and impact of lenvatinib in the SELECT trial, which treated patients with 131I-refractory differentiated thyroid cancer.

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.

Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.

Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses immunotherapy in platinum-resistant bladder cancer.

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.

Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.

Brock O'Neil, MD, physician instructor in urologic surgery, Vanderbilt University, discusses robotic prostatectomy versus open surgery.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses the challenges in treating bladder cancer.

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies in high-grade prostate cancer.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC).

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses the challenges of treating HPV-induced tumors.

Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.

Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.

Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the efficacy of PD-1/PD-L1 inhibitors in melanoma.

Philip McCarthy, MD, professor of oncology, director, Blood and Marrow Transplant Center, Department of Medicine, Roswell Park Cancer Institute, discusses the toxicities associated with lenalidomide for multiple myeloma in the CALGB 100104 study.

Andrew Hendifar, MD, MPH, assistant professor of medicine, Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses PEGPH20 with nab-paclitaxel/gemcitabine in pancreatic cancer.

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.

Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).